Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
November 11 2021 - 3:01AM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, announced today the appointment of Dr. Heiner
Dreismann to its Strategy Advisory Board. Dr. Dreismann had an
illustrious career at Roche where he held multiple executive
positions including, President and Chief Executive Officer of Roche
Molecular Systems, serving as a Member of Roche’s Global Diagnostic
and Executive Committee, and heading-up the Company’s global
business development department.
“To have such a notable leader in the diagnostics
field join our team of advisors, is a testament to what we’re
building at Mainz Biomed,” commented Guido Baechler, Chief
Executive Officer of Mainz Biomed. “His extensive experience and
insight will undoubtedly provide immense value to the company as we
commercially roll-out ColoAlert across Europe, prepare our U.S.
regulatory strategy, and advance a portfolio of next-generation
early cancer detection products that are in development.”
Dr. Dreismann, is a seasoned executive with more
than 35 years of experience in the life sciences and health care
industries and widely regarded as a pioneer in the early adoption
of polymerase chain reaction (PCR) technique, one of the most
ubiquitous technologies in molecular biology and genetics research
today. He joined F. Hoffmann La Roche AG in 1985, and held various
national and international management positions, including head of
manufacturing for microbiological diagnostics, head of R&D
microbiological diagnostics and head of the Business Area
Microbiology. After Roche’s acquisition of PCR technology in 1991,
Dr. Dreismann headed the PCR Business Unit for Europe and strategic
planning for PCR diagnostics. From 2000 to 2006 he was President
and CEO of Roche Molecular Systems in Pleasanton, California. Other
senior positions he held in Roche included Head of Global Business
Development, Roche Diagnostics and Member of Roche's Global
Diagnostic Executive Committee. Dr. Dreismann currently serves on
the boards of several public and private life sciences and health
care companies in the United States, Europe and Israel.
“I am very excited by the
opportunity to serve on Mainz Biomed’s Strategic Advisory Board,”
commented Heiner Dreismann. “I was drawn to the Company by its
impressive technological and business approach to building a
molecular diagnostics franchise anchored by ColoAlert’s core
specifications as well as its differentiated commercial model. I
look forward to working with Guido and the whole Mainz Biomed team
to facilitate progress in expanding ColoAlert’s commercial imprint
across Europe, advancing its regulatory approval in the U.S., and
bringing to market additional early detection home-use diagnostic
solutions for life-threatening conditions."
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular
genetic diagnostic solutions for life-threatening conditions. The
Company's flagship product is ColoAlert, an accurate, non-invasive,
and easy-to-use early detection diagnostic test for colorectal
cancer. ColoAlert is currently marketed across Europe with FDA
clinical study and submission process intended to be launched in
the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s
product candidate portfolio includes PancAlert, an early-stage
pancreatic cancer screening test based on Real-Time Polymerase
Chain Reaction-based (PCR) multiplex detection of molecular-genetic
biomarkers in stool samples, and the GenoStick technology, a
platform being developed to detect pathogens on a molecular genetic
basis.
For more information please visit
www.mainzbiomed.com
For media enquiries, please
contact press@mainzbiomed.com
For investor enquiries, please
contact ir@mainzbiomed.com
Forward Looking Statements
Certain statements made
in this press release are “forward-looking statements” within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be
identified by the use of words such as “anticipate”, “believe”,
“expect”, “estimate”, “plan”, “outlook”, and “project” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements reflect the current analysis of existing
information and are subject to various risks and uncertainties. As
a result, caution must be exercised in relying on forward-looking
statements. Due to known and unknown risks, actual results may
differ materially from the Company’s expectations or projections.
The following factors, among others, could cause actual results to
differ materially from those described in these forward-looking
statements: (i) the failure to meet projected development and
related targets; (ii) changes in applicable laws or regulations;
(iii) the effect of the COVID-19 pandemic on the Company and its
current or intended markets; and (iv) other risks and uncertainties
described herein, as well as those risks and uncertainties
discussed from time to time in other reports and other public
filings with the Securities and Exchange Commission (the “SEC”) by
the Company. Additional information concerning these and other
factors that may impact the Company’s expectations and projections
can be found in its initial filings with the SEC, including its
Prospectus filed on October 12, 2021 and amended on October 25,
2021 and November 1, 2021. The Company’s SEC filings are available
publicly on the SEC's website at www.sec.gov. Any forward-looking
statement made by us in this press release is based only on
information currently available to Mainz Biomed and speaks only as
of the date on which it is made. Mainz Biomed undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024